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A novel inhibitor of tumor necrosis factor- converting enzyme born period with massive kidney enlargement (due to
ameliorates polycystic kidney disease. rapidly expanding cysts) and hepatic fibrosis. ARPKD
Background. Transforming growth factor- (TGF-) expres- occurs in approximately 1:10,000 to 1:40,000 births andsion is abnormal in polycystic kidney disease. We previously
produces significant morbidity and mortality [1]. Data fromdemonstrated that blockade of the epidermal growth factor
experimental models of both recessive and dominantreceptor (EGFR), the receptor for TGF-, significantly slowed
disease progression in the bpk murine model of autosomal- forms of PKD have identified three key pathophysiologic
recessive kidney disease (ARPKD). In the present study, kid- processes in cyst formation and enlargement: increased
ney TGF- expression in this model is characterized, and the cell proliferation, increased fluid secretion, and alteredtherapeutic potential of inhibiting TGF- in ARPKD is exam-
matrix biology [reviewed in 2]. A growing body of evi-ined using a novel inhibitor of tumor necrosis factor- con-
dence has established the central role of the epidermalverting enzyme (TACE), the metalloproteinase that cleaves
membrane-bound TGF- to release the secreted ligand. growth factor receptor (EGFR) in the pathogenesis of
Methods. Immunohistochemistry (IH) and Western analysis cell proliferation in PKD. The EGFR in cystic epithelia
were performed on kidneys from cystic bpk mice and noncystic
is overexpressed and mislocalized to the apical surfacelittermates at postnatal days 7, 14, and 21. Bpk mice and normal
in both ARPKD and ADPKD [3–5]. Apically expressedcontrols were treated with WTACE2, a competitive inhibitor
of TACE, from day 7 until day 21, and the effects on kidney EGFR is capable of binding ligand and transmitting mito-
histology and renal function were assessed. genic signals [6].
Results. Increased TGF- expression by IH was demonstrated Published reports also have suggested that transforming
in the proximal tubules (PT) at postnatal day 7 and collecting
growth factor- (TGF-), a ligand of the EGFR, is ab-tubules (CT) by day 21. A parallel increase in kidney TGF-
normally expressed in PKD. TGF- expression by immu-expression was demonstrated by Western analysis. Treatment
of cystic bpk mice with WTACE2 resulted in a 43% reduction nohistochemistry is increased in kidneys of patients with
in kidney weight to body weight ratio (11.2 vs. 19.7%), im- ADPKD when compared with normal kidneys [7]. In-
proved cystic index (3.2 vs. 4.8), reduced cystic CT to PT ratio creased TGF- mRNA expression as demonstrated by
(1.2 vs. 8), and a greater than 30% reduction in BUN and
Northern analysis is seen in cyst-lining epithelial cellsserum creatinine.
derived from kidneys of patients with ADPKD [8]. MiceConclusions. These findings support the pathophysiological
role of the TGF-/EGFR axis in murine ARPKD and demon- transgenic for TGF- develop renal cysts [9]. TGF- is
strate that inhibition of TGF- secretion has therapeutic poten- present in mitogenic quantities in cyst fluid from bpk mice
tial in PKD. (a murine model of ARPKD), and immunoprecipitation
of TGF- reduces this mitogenic effect (abstract; Sweeney
et al, J Am Soc Nephrol 7:1610, 1996).
Autosomal-recessive polycystic kidney disease (ARPKD) Transforming growth factor- is produced as a prepro-
is an inherited disorder that usually presents in the new- peptide that undergoes further processing at the cell
membrane to produce the secreted moiety [reviewed in 10].
The shedding of the secreted moiety is mediated by tumor
Key words: epidermal growth factor receptor ligand, transforming
necrosis factor- (TNF-) converting enzyme (TACE).growth factor-, autosomal-recessive PKD, proximal tubule cysts, col-
lecting tubule cysts. This metalloproteinase (also called ADAM 17) was ini-
tially recognized as the mediator of TNF- shedding.Received for publication March 21, 2001
However, studies of TACE knockout mice revealed a phe-and in revised form May 18, 2001
Accepted for publication May 21, 2001 notype similar to TGF- knockout mice and confirmed
that these animals had impaired TGF- secretion [11]. 2001 by the International Society of Nephrology
1240
Dell et al: TGF- expression and inhibition in ARPKD 1241
We recently demonstrated that interruption of EGFR and subsequent experiments were obtained from Sigma
(St. Louis, MO, USA), unless indicated.activity by an irreversible inhibitor of receptor tyrosine
kinase activity produced a marked reduction in disease Protein was isolated from whole kidneys by homogeni-
zation in RIPA buffer (phosphate-buffered saline con-severity in murine ARPKD [12]. The current study (1)
characterizes kidney TGF- expression in the bpk model taining 1% nonidet P-40, 0.5% sodium deoxycholate, 0.1%
SDS) with inhibitors [0.1 mg/mL aprotinin, 5 g/mL leu-of ARPKD and (2) examines the therapeutic potential
of blocking TGF- bioavailability in ARPKD using a peptin, 50 g/mL pepstatin, 1 mmol/L ethylenediamine-
tetraacetic acid (EDTA), 1 mmol/L phenylmethylsulfo-novel inhibitor of TACE.
nyl fluoride (PMSF), and 1:100 vol/vol phosphatase
inhibitor cocktail]. Protein content of all samples was
METHODS
determined using the BCA protein assay kit (Pierce, Rock-
The bpk model of ARPKD ford, IL, USA), and equal loading was confirmed by Pon-
seau S solution staining of membranes following transfer.This model arose from a spontaneous mutation in a
colony of BALB/C mice. Affected animals have many For Western blotting, 30 g of total protein lysate was
diluted in SDS reducing buffer [62.5 mmol/L Tris-HCl,similarities to the human disease including collecting tu-
bule (CT) cysts and biliary ectasia and fibrosis [13]. The pH 6.8, 25% vol/vol glycerol, 2% wt/vol sodium dodecyl
sulfate (SDS), 0.01% wt/vol bromophenol blue, 5% vol/kidney disease has a consistent and severe phenotype.
Mice homozygous for the bpk mutation have micro- vol -mercaptoethanol] and subjected to SDS-polyacryl-
amide gel electrophoresis (SDS-PAGE) using a 12% sep-scopic evidence of cyst formation at birth. Proximal tu-
bule (PT) cysts are present at birth, which are gradually arating gel. Samples were transferred to a nitrocellulose
membrane, hybridized with blocking buffer (5% dry milk,replaced by CT cysts as the disease progresses. Cyst
expansion and kidney fibrosis result in death due to renal 0.05% Tween 20) and then hybridized with mouse mono-
clonal anti-TGF- (Research Diagnostics, Flanders, NJ,failure at 24 to 28 days. Heterozygotes show no pheno-
typic abnormalities and are identified by their ability to USA). Membranes were washed and hybridized with per-
oxidase conjugated anti-mouse antibody. Membranes werebreed affected offspring. Unaffected (noncystic) litter-
mates of cystic bpk mice are either wild-type or heterozy- treated with the enhanced chemiluminescence (ECL)
reagent (Amersham Pharmacia Biotech, Piscataway, NJ,gous at the bpk locus.
USA) and exposed to autoradiography film.
Pharmacology of WTACE2 and WAR-1 Cyst fluid from day 21 bpk mice also was examined for
the presence of TGF- by immunoprecipitation; 200 gWTACE2 is a novel metalloproteinase inhibitor spe-
cific for TACE that was developed by Wyeth-Ayerst Re- of total cyst fluid protein was immunoprecipitated with
2 g of primary antibody (polyclonal anti-TGF-; Santasearch (Pearl River, NJ, USA). WTACE2 is a nonpep-
tide sulfonamide TACE inhibitor bearing a hydroxamic Cruz, CA, USA). Then Protein A/G PLUS-agarose (Santa
Cruz) added, and the incubation continued. Pellets wereacid as the requisite zinc-chelating moiety. This nanomo-
lar level inhibitor contains a novel butynyloxybenzene collected by centrifugation, washed, and resuspended in
1  SDS reducing buffer and boiled for two to threeP1 group, derived from analysis of the TACE x-ray struc-
ture, which provides enhanced cellular activity. WTACE2 minutes. Western analysis was then performed as de-
scribed previously in this article.is an orally bioavailable, broad-spectrum inhibitor of ma-
trix metalloproteins (MMPs) with low nanomolar activity
WTACE2 treatment of bpk micein vitro against MMP-1, MMP-9, and MMP-13. WAR-1
is a global matrix metalloproteinase inhibitor that is a Cystic bpk mice and phenotypically normal littermates
were injected with a dose of 100 mg/kg/dose of WTACE2potent inhibitor of MMP-9 and MMP-13, with no mea-
surable activity against TACE. given intraperitoneally once daily, in a vehicle containing
0.5% methocellulose (Fluka Biochemica, Ronkonkoma,
TGF- expression in bpk mice NY, USA) and 2% Tween 80 (JT Baker, Phillipsburg,
NJ, USA), beginning at postnatal day 7. Age-matched un-Kidneys were obtained from cystic bpk mice and non-
cystic littermates at postnatal days 7, 14, and 21. Immuno- treated cystic bpk mice and their noncystic littermates
served as controls. An initial trial (data not shown) dem-histology was performed with modifications as described
previously on formaldehyde-fixed specimens embedded onstrated that vehicle-injected cystic and noncystic mice
had kidney weight to body weight ratios comparable toin plastic [12]. Primary antibody was a polyclonal anti-
TGF- (Chemicon, Temecula, CA, USA) directed against untreated mice. For the studies conducted in this trial,
untreated cystic and noncystic mice served as controls. Atrecombinant 6 kD human TGF- and reactive to mouse.
Tubular localization of antibody staining was assessed day 21, mice were sacrificed. Blood was obtained by orbital
puncture prior to sacrifice. Kidney weight and body weightby staining of serial sections with segment-specific biotin-
ylated lectins, as described [12, 14]. All reagents for these for treated and untreated cystic and noncystic mice were
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measured at sacrifice. Blood urea nitrogen (BUN) was apical staining was seen in CT cysts (DBA/LTA). In
assessed using a colorimetric assay. Serum creatinine the remaining PT cysts, intense apical expression per-
was assessed using standard techniques in the hospital sisted. Cyst fluid staining positive for TGF- also was
laboratory. Differences in clinical and laboratory parame- seen in the lumens of several cysts at advanced stages
ters between treated and untreated cystic and noncystic of the disease. The tubular origin of these very large
mice were analyzed by the two-tailed Student t test. cysts could not be determined by lectin staining. How-
Kidneys were fixed in 4% paraformaldehyde and em- ever, failure of lectin expression in larger cysts is not
bedded in plastic, as described [12]. Segment-specific uncommon in the advanced stages of disease (unpub-
localization of cysts was assessed using lectins specific lished observations) and may reflect deterioration of the
to proximal tubule [Lotus tetragonolobus (LTA)] and epithelium with loss of normal segment-specific markers.
collecting tubule [Dolichos biflorus agglutinin (DBA)]. Lower levels of TGF- expression were seen in PTs
Serial LTA and DBA stained sections were examined and CTs of noncystic littermates, again at a much lower
by light microscopy and assessed for severity of cystic intensity and with minimal apical expression (Fig. 1d).
dilatations in PTs and CTs, expressed on a scale of 0 to Figure 2 demonstrates TGF- expression by Western
5 using a modified cystic index [12]: 0  no cysts; 1  analysis of whole kidney lysates at days 7, 14, and 21
	0.11 mm; 2  0.12 to 0.19 mm; 3  0.20 to 0.27 mm; (early, middle, and late stages of disease) in cystic bpk
4  0.28 to 0.35 mm; and 5  
0.36 mm. The total mice and noncystic littermates. Early in the disease course,
number of CT (DBA/LTA) cysts and PT (LTA/ total TGF- levels were similar. However, with progres-
DBA) cysts within a section were counted and ex- sive disease, there was a marked increased in TGF-
pressed as a ratio. expression in cystic kidneys compared with noncystic
In order to determine whether inhibition of secreted kidneys. TGF- was present in cyst fluid obtained from
TGF- affected total kidney expression of TGF- pro- day 21 bpk mice, as evaluated by immunoprecipitation.
tein, TGF- expression in WTACE2-treated and un- Dominant bands in the whole kidney lysates were noted
treated cystic and noncystic animals was assessed by at 30, 34, and 61 kD and in cyst fluid at 6, 30, and 61 kD.
Western analysis as described previously in this article.
In vivo trials of WTACE2
Treatment with WAR-1, an MMP inhibitor without
A total of 6 cystic bpk mice and 27 noncystic litter-TACE activity
mates were treated with WTACE2. Fifteen age-matched
To determine whether a treatment effect of WTACE2 cystic bpk mice and 30 noncystic littermates served as un-
could be due to its activity against MMPs other than
treated controls. Cystic bpk mice treated with WTACE2
TACE, a limited treatment trial with WAR-1, a novel
showed a significant 43% reduction in kidney weight toMMP inhibitor without TACE activity, was undertaken.
body weight ratio when compared with untreated cysticTwo litters of bpk mice and their noncystic littermates
mice (Table 1). In parallel, kidney weights of treatedwere treated with dosages of 50 mg/kg/day given as once
cystic mice decreased significantly (50% reduction) whendaily intraperitoneal injections. This dose was the highest
compared with untreated cystic mice (0.93 vs. 1.83 g).dose that could be given without significant mortality.
The body weights of treated and untreated cystic miceMice were treated from day 7 of life until day 21 and
did not differ significantly. The treated and untreatedthen sacrificed as described previously in this article.
noncystic mice showed no differences in kidney weights,Analysis of WAR-1–treated mice included assessment
body weights, or kidney weight to body weight ratios.of kidney weight to body weight ratio.
These data, as well as biochemical parameters of treated
and untreated cystic and noncystic mice, are summarized
RESULTS in Table 1. The gross appearance and relative sizes of
representative kidneys from each treatment group areKidney TGF- expression in bpk mice
illustrated in Figure 3. Comparisons of renal functionIn the early stage of disease (day 7), immunohistology
between treated and untreated cystic mice demonstrateddemonstrated markedly increased TGF- expression in
a 30% improvement in BUN (33 vs. 50 mg/dL). A similarPT (LTA/DBA) cysts. As shown in Figure 1a, TGF-
improvement in serum creatinine values (0.18 vs. 0.28expression in PTs localized to both the apical and baso-
mg/dL) was seen but did not reach statistical significance.lateral membranes, with staining particularly prominent
There were no differences in renal function parametersalong the apical membrane. Low levels of TGF- stain-
between the two noncystic groups (Table 1).ing were seen in the PTs of age-matched non-cystic lit-
Daily injections of WTACE2 were generally well tol-termates. However, the intensity of staining was much
erated. All treated mice survived to sacrifice except onelower and minimal apical staining was present (Fig. 1b).
mouse that developed diarrhea at day 18 and died atWith advanced disease in the bpk mouse, CT cysts pre-
dominate. As shown in Figure 1c, TGF- expression with day 20. One additional animal developed diarrhea but
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Fig. 1. Transforming growth factor- (TGF-) expression by immunohistology in bpk kidneys and age-matched noncystic mice at early and late
stages of disease. (a) Immunohistology with polyclonal TGF- (brown-staining) shows intense staining of proximal tubule (PT) cysts (LTA/
DBA) at day 7, with apical staining particularly prominent. Occasional small collecting tubule (CT) cysts (DBA/LTA) also show staining.
(b) Day 7 noncystic kidney has low levels of TGF- staining in the PTs, primarily in the basolateral distribution with minimal apical expression.
(c) As the disease progresses, TGF- expression increases and is present in both CT cysts as well as residual PT cysts, with prominent apical and
basolateral expression, as shown in this day 21 cystic kidney. Large cysts are occasionally seen with peroxidase positive material in the lumen.
The tubular origin of these cysts could not be determined, but are presumed to be CT, as noted in the text (NS  nonstaining for LTA or DBA).
(d) Noncystic day 21 kidney with some TGF- staining evident in the CTs, in a basolateral distribution. Minimal apical staining is evident in CTs
or PTs (original magnification 20).
recovered without apparent ill effects. No other apparent leling the overall reduction in kidney weight to body
weight ratio. The mean PT cystic index in cystic treatedtoxicities were observed.
Histologic characteristics of treated and untreated cys- mice was slightly greater than that of the untreated
groups (1.8 vs. 1.4); however, this difference did nottic mice are summarized in Table 2. Treatment with
WTACE2 was associated with an improvement in cystic reach statistical significance. The ratio of cystic CTs to
PTs was diminished in treated compared with untreatedCT lesions, as illustrated in Figure 4. The mean CT cystic
index of treated cystic mice was 35% less than that of cystic mice (1.2 vs. 8.0), and the values obtained were
similar to those of untreated mutant mice at an earlieruntreated cystic mice (3.2 vs. 4.8). Maximal cyst size in
the treated cystic mice was 0.29 mm compared with a stage of disease [13].
Western analysis of kidneys of treated and untreatedmaximum of 0.41 mm in the untreated cystic mice, paral-
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Fig. 2. TGF- protein expression by Western analysis in early, middle and late disease in bpk mice and noncystic littermates. (A) Western analysis
of whole kidney lysates at day 7, 14, and 21 in cystic bpk mice and noncystic littermates was performed as outlined in the text. TGF- expression
is increased in cystic kidneys compared to noncystic kidneys as disease progresses. Prominent bands are present at 30, 34, and 61 kD in kidney
lysates. (B) Immunoprecipitation of cyst fluid from day 21 cystic bpk mice was performed as described in the text. The mature secreted 6 kD
species is evident; bands at 30 and 61 kD are also present.
Table 1. Clinical parameters of WTACE2-treated and untreated mice
Kidney weight toKidney weight Body weight BUN Creatinine
body weight
Treatment group g % mg/dL
P-21 Cystic (N15) 1.830.6 9.32.2 19.73.4 509a 0.280.13a
P-21 CysticWTACE2 (N6) 0.930.2f 8.21.3 11.21.3f 334bf 0.180.05b
P-21 Noncystic (N30) 0.130.01 9.11.0 1.50.1 194c 0.140.07e
P-21 NoncysticWTACE2 (N27) 0.130.01 8.51.0 1.50.1 174d 0.150.05e
a N  5; b N  4; c N  12; d N  14; e N  10; f P  0.01 cystic treated compared to cystic untreated
Fig. 3. Whole kidney micrograph from day 21
WTACE2-treated and untreated cystic bpk mice
and noncystic littermates. Micrograph demon-
strating relative kidney sizes of WTACE2-treated
and untreated cystic bpk mice and noncystic
littermates. (A) WTACE2-treated noncystic,
(B) untreated noncystic, (C) WTACE2-treated
cystic, and (D) untreated cystic. Kidneys were
harvested at day 21. Cystic-treated mice have
decreased kidney size compared to untreated
cystic mice. Untreated and treated noncystic
kidneys are not significantly different in size.
Table 2. Kidney histology of WTACE2-treated and untreated cystic mice
CT cystic index CT cyst size PT cystic index PT cyst size Cystic CT/PT
Treatment group (graded 1–5) range mm (graded 1–5) range mm ratio
Cystic no treatment (N5) 4.80.4 0.012–0.41 1.40.5 0.012–0.13 8
CysticWTACE2 (N5) 3.20.4a 0.012–0.29 1.80.4 0.012–0.17 1.2a
a P  0.01 cystic treated compared to cystic untreated
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Fig. 4. Histologic appearance of cystic lesions in WTACE-treated and untreated day 21 bpk mice. Lectin binding of day 21 bpk mice (A) untreated
and (B) treated with WTACE2. Immunohistology with biotin-labeled DBA (DBA  browning staining) shows a decrease in the size of CT
cysts as well as a decrease in the relative number of CT cysts. Remaining cysts stained positive for LTA (proximal tubule) on serial sections. A
small percentage of larger cysts were neither DBA nor LTA positive.
cystic and noncystic mice demonstrated a reduction in
overall TGF- expression in treated cystic mice compared
with untreated cystic mice (Fig. 5). There were no differ-
ences in TGF- expression in the two noncystic groups.
A total of 3 cystic bpk mice and 12 noncystic litter-
mates were treated with WAR-1, a global MMP inhibitor
without in vitro activity against TACE (Table 3). The
“relative activity” values shown in Table 3 were derived
from the inverse of the inhibitory concentration 50 (IC50)
and expressed on a scale of 1 to 10 (1, less active; 10, very
active). A higher number, therefore, indicates greater in
vitro inhibition. Treatment of cystic bpk mice with WAR-1
caused a 28% reduction in the kidney weight to body
weight ratio compared with untreated cystic mice. The
reduction in kidney weight to body weight ratio was
less than that of cystic animals treated with WTACE2
(Table 4).
DISCUSSION
Fig. 5. TGF- expression in kidneys of WTACE2-treated and un-
treated day 21 cystic bpk mice and noncystic littermates. Western blot-This study delineates both quantitative and qualitative
ting was performed on whole kidney homogenates as described in theabnormalities in TGF- expression throughout the dis- text. Recombinant human TGF- (molecular weight  6 kD) was
ease course in bpk mice. Prominent TGF- staining pres- loaded in lane 1 as a reference. Kidneys of cystic mice treated with
WTACE2 (lane 4) have a reduction in overall TGF- protein expressionent on the apical surface of PTs early in the disease course
compared with untreated cystic mice (lane 2). There are no differencessuggests a primary abnormality in TGF- expression early in TGF- expression in untreated and treated noncystic kidneys (lanes
3 and 5). No TX  no treatment.in disease. This finding further suggests that PTs may
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Table 4. Treatment effect on cystic kidney disease ofTable 3. Relative in vitro activitya of WTACE2 versus WAR-1
against MMPs 1, 9, 13 and TACE WTACE2 versus WAR-1
Cystic kidney weightTreatment MMP-1 MMP-9 MMP-13 TACE
to body weight
WTACE 2 1.3 0.7 3 1.1 Treatment percent
WAR-1 0 8.2 10 0
WTACE2 (N6) 11.21.3Abbreviations are: WTACE2, competitive inhibitor of tumor necrosis factor-
WAR-1 (N3) 15.31.7converting enzyme; WAR, global matrix metalloprotein; MMP, matrix metallo-
No treatment (N15) 19.73.4protein; TACE, tumor necrosis factor- converting enzyme.
a Expressed on a scale of 1-10 (less active-more active)
decrease EGFR-mediated cell proliferation. We there-
serve as a large source for secreted ligand upstream from fore hypothesize that the decrease in cyst size in mice
CTs. This raises the possibility of paracrine activation of treated with WTACE2 is due to a decrease in the prolif-
EGFR at the earliest stages of disease, which may pro- erative ability of cystic epithelium.
mote CT cell proliferation and cyst development. With An alternative hypothesis for the therapeutic effec-
advanced disease, TGF- is present on the apical (and tiveness of WTACE2 in vivo is alteration of MMPs other
basolateral) surfaces of both CTs and PTs, suggesting a than TACE. Although WTACE2 has specific activity
mechanism by which both paracrine and autocrine acti- against TACE, it is also some degree of in vitro activity
against MMP-1, MMP-9, and MMP-13 (Table 3). MMPsvation of EGFR might occur later in the disease course.
play an important role in remodeling extracellular ma-Western analysis demonstrated a progressive increase
trix, which has been hypothesized as a necessary step forin TGF- expression in whole kidney lysates from cystic
cyst expansion [18]. Recently, a global metalloproteinasemice. Several different protein species were evident on
inhibitor, batimastat, with activity against MMPs, wasthe blots (Figs. 3 and 5). The 34 kD band was present
studied in a rat model of ADPKD. Rats treated withonly in whole kidney lysates but was absent from the
batimastat for eight weeks showed a reduction in cystcyst fluid IP. This suggests that the 34 kD band may be
number and kidney weight (abstract; Obermuller et al,a membrane-bound form. In contrast, the 6 kD form,
Fifth International Workshop on PKD, 2000). Treatmentcorresponding to the mature, secreted moiety was evi-
of cystic mice with WAR-1, an MMP inhibitor with no
dent in cyst fluid but not seen in whole lysates. It there- activity against TACE, also produced a reduction in kid-
fore appears that the relative amount of mature secreted ney weight to body weight ratio, although this was less
ligand, in comparison to total membrane-bound ligands than the reduction seen with WTACE2 treatment (28%
(or higher molecular weight secreted forms), was insuf- compared with 43% with WTACE2). In vitro profiles of
ficient to be detected except in the “enriched” source, WTACE2 and WAR-1 demonstrate that they both share
that is, cyst fluid. The remaining bands may represent some degree of activity against MMP-9 and MMP13, al-
either alternatively processed secreted forms (since they though the activity of WTACE2 is considerably lower
are present in both the whole kidney lysates and the cyst than that of WAR-1 (Table 3). Although the number of
cystic mice treated with WAR-1 was small, the findingsfluid) or nonspecific findings. A variety of TGF- species,
suggest the possibility that the therapeutic benefit ofeither secreted or membrane-bound, ranging in size from
WTACE2 could be due, in part, to inhibition of one or6 to 60 kD, have been reported in normal and malignant
both of these compounds.cells and tissues [15–17].
Epidermal growth factor receptor (EGFR) ligandsWTACE2 is a potent inhibitor of TACE, the enzyme
such as TGF- may directly alter expression of certainthat mediates cleavage of TGF- to release the secre-
metalloproteinases, including MMP-9, in cells that over-ted moiety. This study demonstrates that inhibition of
express EGFR [19, 20]. Both MMP-2 and MMP-9 areTGF- secretion can slow disease progression in mice
up-regulated in murine ARPKD [18, 21]. Principal cells,with ARPKD. Treated mice had a significant reduction
the primary cells affected in ARPKD, express both
in kidney size as well as improvement in renal function. MMP2 and MMP9 [22]. Furthermore, MMP9 expression
A reduction in the CT cystic index in treated mice sug- in these cells is up-regulated by treatment with EGF,
gests that the reduction in kidney size was due to an another EGFR ligand [22]. By inhibiting shedding of
overall decrease in the size of the cystic lesions. The TGF-, WTACE2 may impact indirectly on those path-
most likely explanation for this decrease in cyst size is ways as well. These potential mechanisms for inhibiting
that reduced ligand availability resulted in reduced tubu- cyst growth are not mutually exclusive, and it is possible
lar epithelial cell proliferation. Since cystic CTs express that both are operative in mediating the therapeutic ef-
functional apical EGFR [3, 6], the reduction of biologic- fectiveness of WTACE2.
Tumor necrosis factor- converting enzyme mediatesally active ligand secreted into the lumen is likely to
Dell et al: TGF- expression and inhibition in ARPKD 1247
TGF- shedding, but based on its mode of action, it An additional explanation for differential effects of
TACE and EGFR tyrosine kinase inhibition relates towould not be expected to affect overall expression levels
of the protein. However, when TGF- expression was the complex biology of EGFR ligands. Multiple EGFR
ligands are capable of binding and activating EGFRexamined in kidney lysates of animals treated with the
TACE inhibitor WTACE2, the expression levels of [30, 31]. In addition to EGF and TGF-, which have
been studied in PKD, other ligands that have not beentreated cystic mice were considerably lower than those
of untreated cystic mice (Fig. 5). Kidney TGF- levels studied to date include amphiregulin, heparin-binding
EGF, betacellulin, and epiregulin. Preliminary unpub-of treated and untreated noncystic mice were compara-
ble and lower than those of treated or untreated cystic lished data from our lab suggest that amphiregulin ex-
pression may be aberrant in PKD (abstract; Dell et al,mice. Published reports of malignant and normal cell
lines have shown that EGFR ligands may up-regulate J Am Soc Nephrol 11:388, 2000). At present, there are
their own production (auto-induction) or that of other no published data to indicate whether TACE mediates
EGFR ligands (cross-induction) [23–25]. We hypothe- shedding of the other EGFR ligands. Batimastat, a global
size that by decreasing the availability of secreted ligand, MMP inhibitor, inhibits EGF and AR as well as TGF-
WTACE2 may inhibit these auto-inductive or cross- in vitro [29]. As noted previously in this article, treatment
inductive phenomena. Kidney TGF- expression in cys- with batimastat in a rat model of ADPKD was associated
tic treated mice was still greater than that of noncystic with decreased cyst size and kidney size. However, this
mice, confirming that the aberrant TGF- expression treatment did not effectively inhibit disease progression.
seen in cystic mice was not completely eliminated. In conclusion, this study demonstrates that (1) quanti-
WTACE2 was well tolerated in vivo, and there were tative and qualitative abnormalities in TGF- expression
no apparent toxicities. In particular, there were no un- are present in murine ARPKD and (2) treatment with
toward effects on growth. Mouse weight, kidney weight, an inhibitor of TGF- secretion slowed the progression
and kidney weight/body weight ratios were comparable of renal disease in murine ARPKD. These findings pro-
in treated and untreated noncystic mice. The findings of vide additional support for the hypothesis that EGFR
comparable growth parameters in the treated and un- ligand up-regulation and resultant activation of EGFR
treated noncystic mice suggest that the effects of WTACE2 contributes to the pathogenesis of ARPKD. They further
were not due to a global inhibition of growth. In the suggest that TGF- may have a particularly important
batimastat trial discussed previously in this article, fi- role in this process. These findings suggest that a number
brotic capsules were noted around the kidneys of some of possible therapeutic options may emerge from a better
treated animals, which could have contributed to the de- understanding of the complex interrelationships be-
crease in kidney size reported (abstract; Obermuller et tween the EGFR ligands and the various pathways upon
al, Fifth International Workshop on PKD, 2000). In con- which they act in PKD. The findings of this study and
trast, animals treated with WTACE2 showed no such our previous work also raise the possibility that combina-
abnormalities. tions of therapies directed at EGFR and one or more
The effects of WTACE2 on cystic disease progression of its ligands may be of additional clinical benefit in the
in bpk mice were not as striking as the effects of the treatment of PKD.
EGFR tyrosine kinase inhibitor, EKI-785 [12, 26]. There
are a number of possible explanations for these differences. ACKNOWLEDGMENTS
WTACE2 inhibits production of the secreted moiety of
This work was supported by NIH/NIDDK grant P50DK-57306 andTGF- but has no known activity against membrane- grants from Wyeth-Ayerst Research. Dr. Dell is a recipient of an
bound forms. In vitro studies in other disease processes Individual National Research Service Award (DK-09684). Drs. Levin
and Frost are employees of Wyeth-Ayerst. This research was presentedcharacterized by EGFR overexpression have suggested
in part at the Annual Meeting of the American Society of Nephrology,that membrane-bound forms of the ligand may be able October 2000, and was published in abstract form.
to activate EGFR without the need for processing to the
Reprint requests to Dr. Katherine MacRae Dell, M.D., Departmentsecreted form [27–29]. The relative pathophysiological
of Pediatrics, Rainbow Babies and Children’s Hospital, 11100 Euclidimportance of membrane-bound versus secreted forms Avenue, Cleveland, Ohio 44106-6003, USA.
of TGF- in activating EGFR has not yet been studied in E-mail: kmd8@po.cwru.edu
PKD. Immunohistology demonstrated that TGF- was
present on the apical surface of PTs and CTs in the later REFERENCES
stages of disease. This finding suggests that activation of
1. McDonald R, Watkins SL, Avner ED: Polycystic kidney disease,
apical EGFR on CT cysts could occur by a paracrine in Pediatric Nephrology (4th ed), edited by Barratt TM, Avner
ED, Harmon WE, Baltimore, Lippincott Williams & Wilkins, 1999(secreted TGF- from PTs or CTs) or an autocrine (mem-
2. Murcia NS, Sweeney WE, Avner ED: New insights into the molec-brane-bound TGF- on CTs) mechanism. Inhibition of
ular pathophysiology of polycystic kidney disease. Kidney Int 55:
TACE processing and secretion with WTACE2 would 1187–1197, 1999
3. Orellana SA, Sweeney WE, Neff CD, Avner ED: Epidermalhave little effect on the autocrine pathway.
Dell et al: TGF- expression and inhibition in ARPKD1248
growth factor receptor expression is abnormal in murine polycystic forming growth factor- from the cell surface by an O-glycosylation-
independent multistep process. J Biol Chem 265:6410–6415, 1990kidney. Kidney Int 47:490–499, 1995
18. Rankin CA, Suzuki K, Itoh Y, et al: Matrix metalloproteinases4. Du J, Wilson PD: Abnormal polarization of EGF receptors and
and TIMPS in cultured C57BL/6J-cpk kidney tubules. Kidney Intautocrine stimulation of cyst epithelial growth in human ADPKD.
50:835–844, 1996Am J Physiol 269:C487–C495, 1995
19. O-Charoenrat P, Modjtahedi H, Rhys-Evans P, et al: Epidermal5. Richards WG, Sweeney WE, Yoder BK, et al: Epidermal growth
growth factor-like ligands differentially up-regulate matrix metal-factor receptor activity mediates renal cyst formation in polycystic
loproteinase 9 in head and neck squamous carcinoma cells. Cancerkidney disease. J Clin Invest 101:935–939, 1998 Res 60:1121–1128, 2000
6. Sweeney WE, Avner ED: Functional activity of epidermal growth 20. Kondapaka SB, Fridman R, Reddy KB: Epidermal growth factor
factor receptors in autosomal recessive polycystic kidney disease. and amphiregulin up-regulate matrix metalloproteinase-9 (MMP-
Am J Physiol 275:F387–F394, 1998 9) in human breast cancer cells. Int J Cancer 70:722–726, 1997
7. Lee DC, Chan KW, Chan SY: Expression of transforming growth 21. Rankin CA, Itoh Y, Tian C, et al: Matrix metalloproteinase-2 in
factor alpha and epidermal growth factor receptor in adult polycys- a murine model of infantile-type polycystic kidney disease. J Am
tic kidney disease. J Urol 159:291–296, 1998 Soc Nephrol 10:210–217, 1999
8. Klingel R, Dippold W, Storkel S, et al: Expression of differentia- 22. Piedagnel R, Murphy G, Ronco PM, LeLongt B: Matrix metallo-
proteinase 2 (MMP2) and MMP9 are produced by kidney collectingtion antigens and growth-related genes in normal kidney, autoso-
duct principal cells but are differentially regulated by SV40 large-mal dominant polycystic kidney disease, and renal cell carcinoma.
T, arginine vasopressin and epidermal growth factor. J Biol ChemAm J Kidney Dis 19:22–30, 1992
274:1614–1620, 19999. Lowden DA, Lindemann GW, Merlino G, et al: Renal cysts in
23. Barnard JA, Graves-Deal R, Pittelkow MR, et al: Auto- andtransgenic mice expressing transforming growth factor-alpha. J Lab
cross induction within the mammalian epidermal growth factor-Clin Med 124:386–394, 1994
related peptide family. J Biol Chem 269:22817–22822, 199410. Derynck R: The physiology of transforming growth factor-. Adv
24. Coffey RJ, Derynck R, Wilcox JN, et al: Production and auto-Cancer Res 58:27–52, 1992 induction of transforming growth factor- in human keratinocytes.
11. Peschon JJ, Slack JL, Reddy P, et al: An essential role for ecto- Nature 328:817–820, 1987
domain shedding in mammalian development. Science 282:1281– 25. Shirakata Y, Komurasaki T, Toyoda H, et al: Epiregulin, a novel
1284, 1998 member of the epidermal growth factor family, is an autocrine
12. Sweeney WE Jr, Chen Y, Nakanishi K, et al: Treatment of polycys- growth factor in normal human keratinocytes. J Biol Chem 275:
tic kidney disease with a novel tyrosine kinase inhibitor. Kidney 5748–5753, 2000
Int 57:33–40, 2000 26. Sweeney WE, Futey L, Frost P, Avner ED: In vitro modulation
of cyst formation by a novel tyrosine kinase inhibitor. Kidney Int13. Nauta J, Ozawa Y, Sweeney WE, et al: Renal and biliary abnor-
56:406–413, 1999malities in a new murine model of autosomal recessive polycystic
27. Brachmann R, Lindquist PB, Nagashima M, et al: Transmem-kidney disease. Pediatr Nephrol 7:163–172, 1993
brane TGF- precursors activate EGF/TGF- receptors. Cell 56:14. Nakanishi K, Sweeney WE Jr, Dell KM, et al: Role of CFTR
691–700, 1989in autosomal recessive polycystic kidney disease. J Am Soc Nephrol
28. Wong ST, Winchell LF, McCune BK, et al: The TGF- precursor12:719–725, 2001
expressed on the cell surface binds to the EGF receptor on adjacent15. Bringman TS, Lindquist PB, Derynck R: Different transforming
cells, leading to signal transduction. Cell 56:495–506, 1989growth factor- species are derived from a glycosylated and palmi- 29. Dong J, Opresko LK, Dempsey PJ, et al: Metalloprotease-mediated
toylated transmembrane precursor. Cell 48:429–440, 1987 ligand release regulates autocrine signaling through the epidermal
16. Luetteke NC, Michalopoulos GK, Teixido J, et al: Characteriza- growth factor receptor. Proc Natl Acad Sci USA 96:6235–6240, 1999
tion of high molecular weight transforming growth factor  pro- 30. Wells A: EGF receptor. Int J Biochem Cell Biol 31:637–643, 1999
duced by rat hepatocellular carcinoma cells. Biochem 27:6487– 31. Jones JT, Akita RW, Sliwkowski MX: Binding specificities and
6494, 1988 affinities of egf domains for ErbB receptors. FEBS Lett 447:227–
231, 199917. Teixido J, Wong ST, Lee DC, Massague J: Generation of trans-
